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We report a case of laboratory-confirmed Zika virus 
infection imported into Europe from the Americas. The 
patient developed fever, rash, and oedema of hands 
and feet after returning to Italy from Brazil in late 
March 2015. The case highlights that, together with 
chikungunya virus and dengue virus, three major arbo-
viruses are now co-circulating in Brazil. These arbovi-
ruses represent a burden for the healthcare systems in 
Brazil and other countries where competent mosquito 
vectors are present.
Case presentation
A male Italian traveller in his early 60s presented to 
the Infectious and Tropical Diseases Unit, Azienda 
Ospedaliero Universitaria Careggi, Florence (Italy), four 
days after his return from a 12-day holiday in Salvador 
de Bahia, Brazil at the end of March 2015. The patient 
had a four-day history of confluent slightly-pruritic ery-
thematous rash, diffused on the face, trunk, arms, and 
legs, accompanied by fever (maximum temperature 
38  °C), conjunctivitis, general weakness, and painful 
oedema of both hands and feet. Blood tests revealed 
a normal white blood cell count (6,180 cells/µL; ref-
erence: 4,000–10,000/µL) with normal differential 
count, but some activated lymphocytes, thrombocy-
topenia (112,000/µL; reference: 140,000–440,000/
µL) and slightly elevated C-reactive protein (10 mg/L, 
reference: <9 mg/L). Serum transaminases and creati-
nine were normal. Because of the clinical presentation 
and the travel history, a viral infection was suspected, 
and patient serum was tested for antibodies against 
chikungunya virus (CHIKV), dengue virus (DENV), 
Zika virus (ZIKV), Yellow fever virus, West Nile virus, 
Japanese encephalitis virus, Parvovirus B19, human 
herpes virus 6 (HHV6), and HIV [1]. The serum sample 
taken four days after symptom onset showed a posi-
tive result for anti-ZIKV-IgM and -IgG antibodies, sug-
gesting an acute or recent ZIKV-infection. Results of the 
serological tests for the other viruses tested were neg-
ative (Table). A follow up sample, taken 26 days after 
symptoms onset, showed a threefold increase of the 
anti-ZIKV-IgM and -IgG antibody titres (Table). In addi-
tion, a low-titre DENV IgG was now observed (Table), 
most likely representing a serological cross-reaction of 
the anti-ZIKV-IgG antibodies (Table). ZIKV-specific real-
time reverse transcription-PCR [1] was negative from 
both samples. Generic flavivirus and alphavirus RT-PCR 
[1] were also negative. The presence of ZIKV-specific 
neutralising antibodies in the second serum sample 
was confirmed by a virus neutralisation assay (Table). 
The patient was discharged, managed and followed-up 
in the outpatient department. The patient was recom-
mended symptomatic treatment with paracetamol. The 
symptoms rapidly resolved in the following week (fever 
and rash lasted for only four days).
Background
ZIKV is an arbovirus belonging to the flavivirus genus 
that was first isolated from a rhesus monkey in the 
Zika forest in Uganda [2]. It is transmitted by differ-
ent species of Aedes mosquitoes. Clinical manifes-
tations of ZIKV infection are very similar to those of 
DENV and CHIKV infections, but usually milder [3]. 
Human infections have been documented in several 
African and south-eastern Asian countries [4]. ZIKV 
was responsible for several outbreaks on islands in the 
Pacific Ocean, such as Yap Island (Federated States 
of Micronesia in 2007 [4]) and more recently in French 
Polynesia, New Caledonia, Easter Island and the Cook 
Islands in 2013 [5,6]. In several non-endemic countries 
including Japan, Germany, Italy, Canada, Australia and 
the United States (US), the infection has been diag-
nosed in returning travellers [1,7-11].
ZIKV infections have recently been reported in Brazil, 
where the virus has probably been circulating since 
2014 [12]. So far, 16 cases have been confirmed in 
accordance to the Ministry of Health of Brazil [13].The 
emergence of ZIKV in Brazil is of concern since Brazil is 
the country with the highest number of DENV infections 
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world-wide [14]. Moreover, CHIKV has been introduced 
to South America as well with more than one million of 
cases diagnosed since 2013 to date [15]. 
Discussion and conclusions
The ongoing outbreak of now two major mosquito-
borne infections in addition to endemic DENV infec-
tions has the potential of posing a serious threat to 
local and supra-national South American healthcare 
systems, as observed in the Pacific region in recent 
years [16].
In endemic areas, but also in the setting of travel medi-
cine, ZIKV infection represents both a clinical and diag-
nostic challenge since the symptoms are very similar to 
other arboviral diseases, no specific commercial sero-
logical tests are available, and cross-reactive DENV 
serology (IgG or IgM) during ZIKV infection has been 
described in previously reported cases [11] which may 
lead to incorrect diagnoses. Recently, neurological com-
plications possibly related to coinfections or sequen-
tial infections with dengue virus have been reported in 
French Polynesia [17].The European Centre for Disease 
Prevention and Control (ECDC) published a Rapid Risk 
Assessment on ZIKV in the Americas on 25 May 2015, 
with the aim of increasing awareness and enhanc-
ing vigilance towards the detection of imported cases 
of ZIKV infection in Europe [18]. This case is, to the 
best of our knowledge, the first laboratory-confirmed 
case of a ZIKV infection acquired in the Americas and 
imported into Europe. The patient had returned to Italy, 
his home country, where Aedes albopictus, a potential 
competent vector, is widely distributed. Considering 
the extensive airline travel between Latin America and 
other parts of the world where the viruses have not yet 
been established, but competent vectors are present, 
such as southern Europe and the southern part of the 
US, the surveillance systems have to be aware of the 
appearance of ZIKV in Brazil to avoid further dissemi-
nation of the disease. In order to prevent seeding of 
ZIKV into local mosquito populations, as it happened 
for CHIKV in Italy in 2007 and in France in 2010 and 
2014 [19, 20, 21], screening of febrile returning travel-
lers for arboviral infections, especially in the summer 
months, is highly advised.
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